TARGETED DISRUPTION OF PANCREATIC-DERIVED FACTOR (PANDER, FAM3B) IMPAIRS PANCREATIC β-CELL FUNCTION

Running title: Impaired β-cell function in PANDER-/-

Claudia E. Robert-Cooperman1, Jason R. Carnegie1, Camella G. Wilson2, Jichun Yang1, Joshua R. Cook2, Jianmei Wu1, Robert A. Young1, Bryan A. Wolf1,2, and Brant R. Burkhardt1

1Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia Research Institute,
2University of Pennsylvania School of Medicine, Philadelphia, PA, USA 19104.

Corresponding Author:
Dr. Brant R. Burkhardt, Ph.D.,
Email: burkhardtb@mail.med.upenn.edu

Submitted 20 October 2009 and accepted 14 June 2010.

This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
**Objective** - PANcreatic-DERived factor (PANDER, FAM3B) is a pancreatic islet-specific cytokine-like protein that is secreted from β-cells upon glucose stimulation. The biological function of PANDER is unknown and to address this we generated and characterized a PANDER knockout mouse.

**Research design and methods** - For generation of the PANDER knockout mouse, the PANDER gene was disrupted and expression inhibited by homologous recombination via replacement of the first two exons, secretion signal peptide, and transcriptional start site with the neomycin gene. PANDER<sup>−/−</sup> mice were then phenotyped by a number of *in-vitro* and *in-vivo* tests to evaluate potential effects on glucose regulation, insulin-sensitivity, and β-cell morphology and function.

**Results** - Glucose tolerance tests demonstrated significantly higher blood glucose levels in PANDER<sup>−/−</sup> versus wild-type male mice. To identify the mechanism of the glucose intolerance, insulin sensitivity and pancreatic β-cell function were examined. Hyperinsulenic-euglycemic clamps and insulin tolerance testing showed similar insulin sensitivity for both the PANDER<sup>−/−</sup> and wild-type mice. The *in-vivo* insulin response following i.p. glucose injection surprisingly produced significantly higher insulin levels in the PANDER<sup>−/−</sup>, whereas insulin release was blunted upon arginine administration. Islet perifusion and calcium imaging studies showed abnormal responses of the PANDER<sup>−/−</sup> islets to glucose stimulation. In contrast, neither islet architecture nor insulin content was impacted by the loss of PANDER. Interestingly, the elevated insulin levels identified *in-vivo* were attributed to decreased hepatic insulin clearance in the PANDER<sup>−/−</sup>. Taken together, these results demonstrated decreased pancreatic β-cell function in the PANDER<sup>−/−</sup> mouse.

**Conclusions** - These results support a potential role of PANDER in the pancreatic β-cell for regulation or facilitation of insulin secretion.

PANcreatic-DERived factor (PANDER, FAM3B) is a 235-amino acid protein secreted predominantly from pancreatic α- and β-cells and appears to colocalize with both insulin and glucagon (1;2). The initial discovery of PANDER was the result of a computational algorithm, ostensible recognition of folds (ORF), in an attempt to identify novel cytokines based on the prediction of secondary structure. From ORF, it was hypothesized that the secondary structure of PANDER contained a four-helix bundle with a typical up-up-down-down topology also found in numerous cytokines.

Initial *in-vitro* experiments evaluating the impact of PANDER on pancreatic islets demonstrated the induction of apoptosis in primary islets (mouse, human, and rat) or islet-derived cell lines either by exogenous recombinant protein application or intracellular adenoviral delivery via a caspase-3 dependent mediated mechanism (2-4). Furthermore, microarray analysis of PANDER-treated islets demonstrated the activation of various cell death pathways via both caspase-3 and cyclin-dependent kinase inhibitor 1A (p21) (5). However, despite these *in-vitro* results demonstrating a potential role for PANDER in islet apoptosis, our first
animal model exploring function of PANDER did not recapitulate these findings. Transgenic mice that have pancreatic-duodenal homeobox-1 (PDX-1)-driven targeted overexpression of PANDER specifically in pancreatic β-cells display normal β-cell mass and function, but exhibit a glucose intolerant phenotype following a high fat diet (6). The mechanism of this observed glucose-intolerance is still being elucidated. However, the liver is a potential target for PANDER and may be central to the observed glucose-intolerance (7). Iodinated recombinant PANDER has been shown to bind to liver membranes. Pre-treatment of liver-derived HepG2 cells with PANDER resulted in significant inhibition of insulin-stimulated activation of the insulin receptor, insulin receptor substrate 1 (IRS-1), phosphatidylinositol-3′-OH-kinase (PI-3 kinase), and Akt indicating the potential involvement of PANDER in regulation of hepatic insulin signaling pathways. Further evidence of PANDER’s potential role in regulating glycemia has been generated by the influence of glucose on PANDER expression. Glucose has been demonstrated to (i) increase secretion of cleaved PANDER and production of full-length PANDER in both insulinoma cells and primary islets (8); (ii) upregulate PANDER mRNA (9); and (iii) induce promoter activity (10). In addition, the critical pancreatic β-cell specific transcriptional factor of PDX-1 binds to the PANDER promoter (11). Glucose has been demonstrated to induce PANDER gene expression via multiple signaling pathways that include Ca2+-PKA-ERK1/2-CREB and Ca2+-PKC-CREB mechanisms (9). Furthermore, glucose regulated PANDER gene expression in MIN6 cells is dependent upon both PI-3 kinase and ROS-related pathways. Much of the data surrounding PANDER certainly suggests a potential role in glucose homeostasis but the lack of a knockout animal model has hindered the elucidation of the biological function of PANDER. To address this, we have for the first time generated and characterized a PANDER knockout mouse. Deletion of PANDER has resulted in glucose intolerance with impaired insulin secretion and reveals an unpredicted role for PANDER in pancreatic β-cell function.

**RESEARCH DESIGN AND METHODS**

**Construction of PANDER targeting vector and knockout mice.** A mouse 129/Sv genomic bacterial artificial chromosome (BAC) clone containing 14 kb of PANDER sequence with the flanking DNA of our potential targeted region was utilized as a template to create both the long and short arms of the targeting vector. An approximate 4.3 kb long-arm genomic fragment containing the PANDER promoter was amplified by forward primer, 5′-GCGGTACC GCCCTGGCTGTTCTGGAAC TAA-3′, and the reverse primer, 5′-GAGGATCC GACCCAGTGTGGTGCCA-3′, and cloned in opposite orientation of the neomycin gene using the KpnI and BamHI sites within cloning site A of the OSDUPDEL (courtesy of Youhai Chen, University of Pennsylvania) plasmid (incorporated restriction sites are underlined) (Fig. 1A). The approximate 2.9 kb short-arm genomic fragment containing intron 2 of the PANDER gene was amplified with forward primer, 5′-GGCAGTGCTGTCATTCAAGCATTGGG A-3′, and reverse primer, 5′-GCCCTAGGCCTAAACATAGGTCTTCT A-3′, and cloned in opposite orientation of the neomycin gene using the PmlI and NheI sites, respectively. Thymidine kinase gene was inserted at the 3′ end of the short arm of the targeting vector for negative selection. This targeting vector was created to remove the first 54 amino acids of PANDER encompassing the transcriptional and translational start site, secretion signal peptide, and helix A. From a total of 288 clones generated by the University of
Pennsylvania Gene Targeting Core, two were identified by PCR that were correctly recombined. Correct insertion of the 5’-arm and replacement of a portion of the PANDER gene with neomycin was confirmed by PCR amplification using the forward primer located in the PANDER promoter region of 5’-CTTGTGATGGTGATGCCAGTT-3’, and the reverse primer located in the neomycin gene of 5’-CTTCCTCGTGCTTTACGGTATC-3’.

Confirmation of the 3’-arm was performed with the forward primer located in the neomycin gene of 5’-CCGAATAGCCTCTCCACCCAA-3’ and reverse primer located in intron 2 of the PANDER gene of 5’-GCCACTGCACTAAAAGAAAGA-3’. Both primer sets were utilized under the following cycling conditions: 1 cycle of 94°C for 2 min and 35 cycles of 94°C for 30 s, 60°C for 30 s, and 68°C for 4 min and 30 s followed by 1 cycle of 68°C for 5 min employing the use of Accuprime Taq DNA polymerase (Stratagene). Chimeric mice were produced by microinjection of the correctly targeted cell clone into E3.5 C57BL/6 blastocysts, and transferred to pseudopregnant foster mothers. High percentage male chimeras (70% or greater) were then chosen for subsequent mating with C57BL/6 females, and germline transmission was confirmed by PCR as described above. Chimeras were subsequently generated from the targeted ES cells and bred to C57BL/6 mice with germ line transmission. PANDER +/- mice were subsequently bred to homogeneity and genomic confirmation was performed by PCR using primers to encompass the entire targeted region. Primers utilized for this PCR confirmation are described above as the forward primer located in the 5’ PANDER promoter region and the reverse primer located in intron 2. PCR conditions were the same as described above with the exception of the extension cycle increased from 68°C for 4 min 30 s to 12 min. The wild-type PANDER gene resulted in a 12.1 kb product, and the recombinant PANDER knockout allele in a 8.3 kb product. All mouse procedures adhered to the approved protocols by the University of Pennsylvania and Children’s Hospital of Philadelphia Institutional Animal Care and Use Committee.

**Quantitative analysis of gene expression via RT-PCR.** Various tissues were collected from PANDER+/+, +/-, and -/- mice and immediately snap frozen in RNA later (Qiagen). RNA was then isolated using the RNeasy kit (Qiagen) following manufacturer’s instructions. Purity and quantity of the isolated RNA was determined by the A260/A280. RT-PCR of the PANDER gene was performed as previously described (2). Primers for detection of various genes involved in glucose stimulated insulin secretion were purchased commercially (ABI AppliedBiosystems). Relative levels of mRNA expression were normalized to β-actin or 18S rRNA, and calculated using the 2^{-ΔΔCT} method.

**Immunoblotting.** Pancreatic islets were isolated from mice using the standard collagenase method as previously described (2). Cell lysates were prepared, analyzed, and electrotransferred to PVDF membrane as previously described (2). Detection was performed using a rabbit polyclonal PANDER antibody that was produced via Genomic Antibody Technology™ (Strategic Biosolutions). Immunoblots were incubated with primary antibody at a dilution of 1:1000 in 1x Tris-buffered saline with Tween (TBST) (10 mmol/l Tris base, 100 mmol/l NaCl, 0.1% Tween-20, pH 7.5) and 2% blocking solution (GE Healthcare) at 4°C overnight. The membrane was washed five times with 10 ml 1x TBST, and incubated in 1:20,000 peroxidase-conjugated donkey anti-rabbit antibody at room temperature for 1 h before washing as above, and then developed with enhanced chemiluminescence. For
confirmation of equivalent loaded protein, following the detection of the PANDER immunoblot, PVDF membrane was stripped with Restore™ Western Blot Stripping Buffer (Pierce Biotechnology) and reprobed using 1:500 β-actin antibody (Santa Cruz Biotechnology, sc-8432). Detection was performed using the enhanced chemiluminescence western blotting detection reagents (GE Healthcare). Measurement of glucokinase (sc-7908) and Kir6.2 (sc-20809) expression in pancreatic islets was performed as described above.

**Glucose/insulin tolerance and arginine stimulation tests.** For glucose tolerance tests (GTT), mice were fasted overnight (approximately 16 hours) and subsequently injected intraperitoneally with 2 grams of glucose (Fisher Scientific) per kilogram of body weight. Glucose levels were measured at 0, 15, 30, 60, 90, and 120 minutes with a Freestyle® glucometer via tail vein blood sampling (approximately 5 μl). Measurement of plasma insulin concentration during the GTT was performed by obtaining blood collected from the tail vein in a Microvette® CB 300 (Sarstedt) followed by centrifugation for serum separation and collection. Sera samples were then frozen at -80°C prior to insulin content analysis. Plasma insulin levels were determined by using the Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem). For insulin tolerance tests, mice were fasted for 4 hours and then injected intraperitoneally with 0.75 units of insulin (NovoLog®) per kilogram of body weight. Glucose levels were measured as described above. For arginine stimulation tests, mice were fasted overnight and then injected intraperitoneally with 2 grams of arginine (Sigma) per kilogram of body weight. Blood glucose and serum insulin levels were obtained as previously described above.

**Hyperinsulinemic-euglycemic clamp and hepatic glucose production calculation.** Clamp studies were performed and calculations determined by the University of Pennsylvania Mouse Phenotyping Core as previously described (12).

**Islet perifusion studies.** Islet perifusions were performed as previously described (3). In brief, freshly isolated and hand-picked murine islets (approximately 100) were collected under a stereomicroscope, washed twice with Krebs-Ringer bicarbonate buffer (KRB), and loaded into a 13-mm chamber containing a nylon membrane filter held at 37°C in a water bath. Islets were first perifused with KRB containing 0 mM glucose for 1 h followed by a run perifusion consisting of increasing glucose conditions. Insulin content of effluent fractions and islet lysate were determined by radioimmunoassay. Immunofluorescence. Immunofluorescence was performed on pancreatic sections as described previously utilizing confocal microscopy (Leica Microsystems Inc.) (2). The following antibodies were used: guinea pig anti-insulin (1:200 dilution; Linco), mouse anti-glucagon (1:200 dilution; R&D Systems), anti-guinea pig alexa-fluor488 (1:5000, Invitrogen), and anti-mouse alexa594 (1:5000, Invitrogen).

**Calcium Imaging of Isolated Pancreatic Islets.** Murine pancreatic islets were isolated as described above and cultured for 3 days in complete RPMI. Islets were pooled from three mice per each genotype and then loaded with 15 µM Fura-2 acetoxymethylester (Fura-2AM) (Molecular Probes). Calcium imaging of the isolated islets was performed as described before (13). In brief, Fura-2AM-loaded islets were then transferred to a perifusion chamber and placed on a homeothermic platform of an inverted Zeiss microscope for calcium evaluation with a 40x oil-immersion objective. Islets were then perifused with Krebs bicarbonate buffer at 37°C at a flow rate of 2 ml/min while increasing concentrations of glucose in Krebs buffer were applied with a terminal application of 30 mM KCl.
calcium concentration was determined by the ratio of the excitation of fura-2AM at 334 nm to that at 380 nm. Emission was measured at 520 nm with an Attofluor Ratio Vision Software (BD Biosciences).

**ATP/ADP Assays.** ATP and ADP content was measured from 100 isolated murine islets pooled from two mice per each genotype and then stimulated during static incubation with glucose as previously described (14).

**Hepatic Insulin Clearance.** For estimating insulin clearance, the ratio of C-peptide (ng/ml) over insulin (ng/ml) area under the curve (AUC) was calculated from the mean serum levels obtained during a GTT (described above) from multiple time points (0, 30, and 120 minutes post-IP glucose injection). Insulin concentration was calculated as described earlier and the C-peptide levels were determined using the Mouse C-Peptide II ELISA (ALPCO).

**Measurement of Glucagon-like peptide-1 (GLP-1).** Mice were fasted overnight (approximately 16 hours) and then exposed to a 4 hour refeed in which chow was added back to respective cages and mice were allowed to feed ad libitum. Following the refeeding period, mice were sacrificed and blood was collected in a Microvette® CB 300 (Sarstedt) followed by centrifugation for serum separation and collection. Sera samples were then frozen at -80°C prior to GLP-1 analysis. Total GLP-1 levels were determined from 50 µl of sera using the GLP-1 (7-36 and 9-36) ELISA kit (ALPCO).

**Statistical Analysis.** Data are presented as mean ± S.E.M. Statistical significance of differences between groups was analyzed by paired Student’s t test utilizing programs resident to Graphpad Prism version 5.01. A p value less than 0.05 was considered statistically significant.

**RESULTS**

**Generation and confirmation of PANDER knockout mice.** The PANDER gene was disrupted in ES cells by homologous recombination using a targeting vector that would replace the first two exons (54 amino acids), secretion signal peptide, and transcriptional start site with the neomycin gene inserted in opposite orientation (Fig. 1A). Two ES clones out of 288 were identified as correctly targeted (Fig. 1B), and utilized to generate chimeric male mice that passed the disrupted PANDER gene to the offspring (Fig. 1C). PANDER +/- mice were then bred to homogeneity to create PANDER +/- knockouts (Fig. 1D). To confirm complete absence of PANDER expression, particularly in the PANDER restricted tissues of pancreatic islets and intestine, both RT-PCR and western analysis were performed. PANDER mRNA expression was evaluated in the various PANDER negative tissues of liver, spleen, kidney, and brain, and PANDER positive tissues of isolated pancreatic islets, and small intestine. PANDER mRNA was not detected above background in both islets and small intestine from PANDER +/- mice with marked reduction found in PANDER +/- mice (Fig. 1E). As expected, PANDER message was not detected in PANDER negative tissues (data not shown). Western analysis of protein isolated from pancreatic islets of PANDER +/- mice demonstrated the absence of full-length PANDER protein whereas a marked reduction was observed in heterozygotes (Fig. 1F).

**Metabolic evaluation of PANDER +/- mice.** PANDER +/- mice were intercrossed to generate a total of 233 offspring that were born with the expected Mendelian distribution with no observed increase in embryonic lethality (data not shown). There were no significant differences in size, appearance, or 24 or 48 hour fasting levels of glucose, insulin, and glucagon among PANDER +/-, +/-, and +/- mice (data not shown). We initially evaluated the impact of PANDER deletion on glucose tolerance. Glucose tolerance tests (GTT’s) demonstrated higher blood glucose
levels in PANDER−/− versus wild-type (WT) 4 to 6 month old male mice (Fig. 2A). Glucose intolerance was also observed in younger 3 month old male mice (data not shown). Glucose intolerance was not observed in littermate and genotype matched females (data not shown). After glucose injection, the elevation in blood glucose levels was significantly higher in PANDER−/− mice as compared to WT mice for a majority of the evaluated time-points with a significant difference observed (P < 0.001) when determining total area under the curve for all glucose readings during the course of the GTT (Fig. 2B). The observed glucose intolerance may be attributed to either decreased peripheral insulin sensitivity or impaired glucose stimulated insulin secretion (GSIS). To determine if the observed glucose tolerance was the result of impaired insulin sensitivity, insulin tolerance tests and hyperinsulinemic-euglycemic clamps were performed. Both evaluations demonstrated similar insulin sensitivity for both the PANDER−/− and WT mice (Figs. 2C and 2D). Evaluation of GSIS was performed by measuring plasma insulin levels at various time points following glucose injection. Surprisingly, plasma insulin levels were significantly higher in PANDER−/− mice at the 30, 60, and 120 min time points (Fig 2E). The lack of concordance between the observed result of glucose intolerance and higher insulin levels warranted further investigation. To further measure the in-vivo insulin response of PANDER−/− murine islets, we performed administration of the nonglucose secretagogue, arginine. The acute insulin response (1-5 min following arginine injection) was significantly inhibited in the PANDER−/− mice (Fig. 2F). Overall, these findings implicate that PANDER serves a potential role in the maintenance of post-prandial glucose homeostasis.

**Decreased hepatic glucose production during hyperinsulinemic-euglycemic clamp.** During the hyperinsulinemic-euglycemic clamp, hepatic glucose production was evaluated (Fig. 3A). Basal hepatic glucose production was similar between PANDER−/− and WT mice (72.6 ± 7.0 vs. 71.1 ± 7.5 mg/kg/min, respectively; P = NS). However, hepatic glucose production in PANDER−/− mice was significantly lower than WT mice during clamp conditions (18.6 ± 2.1 vs. 29.3 ± 4.2 vs. mg/kg/min, respectively; P < 0.05). Percentage of hepatic glucose production suppression during the clamp was concordantly higher in PANDER−/− mice but narrowly missed statistical significance (73.4 ± 3.0 vs. 53.3 ± 8.9%, respectively; P = 0.05) (Fig. 3B).

**Loss of PANDER does not impact islet architecture or gene expression.** Since neither insulin sensitivity nor hepatic glucose production appeared to be the cause of the observed glucose intolerance, we next examined if the absence of PANDER in the pancreatic β-cell resulted in altered islet architecture or gene expression. Therefore, immunofluorescence was performed using antibodies recognizing the pancreatic hormones of glucagon and insulin to label the major islet cells of α- and β-cells, respectively (Fig. 4A). Both WT and PANDER−/− mice contained both pancreatic islet cell types, with insulin positive β-cells localized to the core of the islet, and the smaller glucagon-positive α-cell population localized to the mantle of the islet. Overall, immunofluorescent evaluation indicated no discernable difference in islet architecture. To evaluate any potential differences in mRNA expression for genes involved in GSIS, quantitative RT-PCR was performed on isolated pancreatic islet RNA (Fig. 4B). The measured islet genes are involved in multiple steps of GSIS and included glucose-sensing and transport (glucose transporter 2), glycolysis (glucokinase), K+ channel (Kir6.2/Sur1), Ca2+ pumps (Serca2/3), and exocytosis (VAMP2, Rab3a, and Munc18c). All of the genes were
expressed at similar levels for WT and PANDER−/− islet RNA. Western analysis of isolated islets from PANDER KO and WT mice revealed similar expression levels of GK and Kir6.2, despite the appearance of increased expression via RT-PCR (data not shown). Overall, intact islet architecture with similar islet gene expression in the absence of PANDER demonstrates that the observed glucose intolerance is unlikely attributed to impaired islet development but rather suggests the potential loss of β-cell function. Inhibited glucose-stimulated insulin secretion from isolated islets of PANDER−/− mice. To further characterize islet function in isolation and separate from systemic effects, we performed insulin secretion studies on perifused islets isolated from both PANDER−/− and WT mice (Fig. 5A). Isolated islets were treated with increasing glucose concentrations ranging from 0-30 mM glucose followed by depolarization with KCl stimulation at the end. WT islets produced a robust insulin secretory response to glucose. However, PANDER−/− islets displayed a significantly decreased insulin response to increasing concentrations of glucose as compared to WT islets (1.0 ± 0.1 vs. 5.3 ± 1.7 AUC, respectively; P < 0.05) (Fig. 5B). Both WT and PANDER−/− islets responded similarly to depolarization via KCl at the conclusion of the experiment (1.7 ± 0.2 vs. 3.4 ± 1.1 AUC, respectively, P = NS) (Fig. 5C). To further characterize if the insulin secretory defect is attributed to decreased insulin production, insulin content was also measured from isolated islets (Fig. 5D). Insulin levels were equivalent in both WT and PANDER−/− islets (5272 ± 1311 vs. 7565 ± 1049 ng/ml/50 islets, respectively; P = NS). Together, these results suggest that PANDER impacts pancreatic β-cell function with a potential role in mediating GSIS.

PANDER deficient islets display normal glucose metabolism with altered Ca2+ response to both glucose and KCl. The inhibited insulin secretion found in PANDER−/− islets did not appear to be based at the level of islet architecture, metabolic gene expression, or insulin content, and therefore suggested a potential disruption of glucose metabolism or generation of secondary signals required for initiating insulin exocytosis. To evaluate both glucose metabolism and generation of secondary signals, we measured the ATP/ADP ratio and intracellular Ca2+, respectively, from both PANDER−/− and WT isolated islets At physiological glucose concentrations (2, 5, and 10 mM), the ATP/ADP ratio in PANDER−/− islets were indistinguishable from those of WT islets (data not shown). These results suggest that glucose-metabolism is maintained in PANDER−/− islets and this was consistent with the maintenance of normal gene expression of the various metabolic genes of GLUT2 and glucokinase. For evaluation of secondary signals, changes in cytosolic Ca2+ during glucose and KCl stimulation were monitored by Fura-2 fluorescence imaging (Fig. 6). The intracellular Ca2+ response in PANDER−/− islets differed from WT islets by the following observations: hyper-response of calcium at the 3 mM condition; lack of calcium dip attributed to sarco-endoplasmic Ca2+-ATPase (SERCA) (15;16) immediately preceeding the rapid rise in intracellular calcium at 16 mM glucose observed in WT; overall amplitude was modestly decreased following 16 mM glucose; and decreased KCl response. However, both PANDER−/− and WT islets promptly returned to baseline following 0 mM glucose condition. The abnormal calcium handling of PANDER−/− mouse islets may potentially indicate a mechanism for the impaired GSIS observed in-vitro and glucose intolerance with blunted arginine response observed in-vivo. Decreased insulin clearance in PANDER−/− mice. The incongruity of the data indicating a defect in GSIS of the PANDER−/− islets with
the otherwise higher levels of circulating insulin detected during the GTT potentially indicated altered insulin clearance especially in the presence of normal insulin tolerance. C-peptide is cosecreted with insulin at equimolar amounts, but in contrast to insulin, passes the liver without considerable extraction with a half-life ten-fold higher than that of insulin (17;18). Therefore, many studies have evaluated insulin clearance based on the changes in C-peptide-to-insulin ratios determined at single or multiple time points (19;20). We employed this same indirect approach to investigate potential alterations in hepatic insulin clearance (Fig.7). Insulin and C-peptide concentrations increased robustly following glucose administration for both PANDER−/− and WT islets (Figs. 7A and 7B). However, as observed previously (Fig. 2E) insulin levels were higher in the PANDER−/− as compared to WT mice (Fig. 7A). In contrast, C-peptide levels were initially higher in PANDER−/− mice, but then similar to WT following glucose stimulation (Fig. 7B). The overall C-peptide-to-insulin ratio was reduced significantly in PANDER−/− mice indicating a potential impairment in hepatic insulin clearance (Fig. 7C).

DISCUSSION
The biological function of PANDER has remained elusive since its initial discovery in 2002. Our previous reports and a publication from another research group have suggested a potential role for PANDER in glucose homeostasis, however, the lack of a knockout mouse has hindered further biological evaluation. Our investigation has attempted to directly address this limitation via creation of a PANDER−/− mouse and further establish a functional role for PANDER in the maintenance of glucose homeostasis. Targeted disruption of PANDER did not result in increased embryonic lethality or gross morphological differences between PANDER−/−, +/+ or WT mice. However, PANDER−/− male mice displayed glucose-intolerance, whereas littermate and genotype matched females were indistinguishable. However, it is not unusual for a glucose-intolerant phenotype to be more severe in male versus female mouse models (21-23). Interestingly, our PANDER transgenic model also displays a male-specific phenotype (6). Deletion of PANDER did not appear to alter fasting levels of various hormones (ie. insulin, glucagon, amylin, or leptin), and the metabolic defect occurred in the PANDER−/− mice during periods of nutrient challenge (ie. glucose) suggesting that PANDER serves a putative role in regulating post-prandial glucose homeostasis rather than maintaining basal normoglycemia.

PANDER−/− male mice are glucose-intolerant and isolated islets appear to exhibit an insulin secretory defect in response to glucose (in-vitro), arginine (in-vivo), and display an abnormal calcium response to both glucose and KCl. Indeed it has been proposed that decreased GSIS can be attributed to abnormal Ca2+ handling of pancreatic islets as have been reported in the islets obtained from the type 2 diabetic models of the Goto-Kakizaki and neonatal streptozotocin rat (24;25). An additional reported defect in Ca2+ handling has been the absence of the initial sequestration of Ca2+ by β-cell SERCA found in diabetic db/db murine islets (26). The initial Ca2+ dip following glucose stimulation is dependent upon functional SERCA and appears to serve a critical role in GSIS. However, mRNA levels of SERCA2/3 were similar between PANDER−/− and WT mice but activity has yet to be evaluated. Overall, the defective Ca2+ handling observed in the PANDER−/− islets may provide a causative mechanism for the impaired GSIS.

A peculiar caveat to our results was discordance between the higher insulin levels found in-vivo during the glucose-tolerance test and impaired insulin secretion in-vitro in the PANDER−/−. Protective and compensatory
mechanisms may exist in-vivo that preserve and maintain β-cell function, whereas these defects are substantially exaggerated and identified in isolated islets. Also, circulating insulin levels not only reflect secretion but also clearance, and therefore suggests PANDER−/− mice may also have altered hepatic insulin clearance. Indeed, our model displayed decreased insulin clearance and suggested that PANDER may have a role in impacting liver function or this may serve as a compensatory mechanism to counteract impaired insulin secretion. Interestingly, other knockout models have also demonstrated a similar phenotype of impaired β-cell function with in-vivo hyperinsulinemia. The deletion of hepatocyte nuclear factor-4α (HNF-4α) in pancreatic β-cells resulted in hyperinsulinemia in fasted and fed mice but also demonstrated impaired glucose tolerance and abnormal responses of the isolated HNF-4α−/− islets by both islet perifusion and calcium imaging (27). In addition, the glucagon receptor knockout (Gcgr−/−) mouse demonstrated higher insulin levels following a tail-vein injected glucose challenge, yet revealed a blunted glucose-stimulated insulin response in isolated islets at high glucose concentrations (28). In Gcgr−/− mice, the impaired GSIS was restored and enhanced due to increased levels of biologically active GLP-1. However, PANDER−/− did not demonstrate increased post-prandial serum GLP-1 levels as compared to WT mice (data not shown) and suggests that the incongruity of the observed defect in GSIS with the otherwise higher levels of circulating insulin detected during GTT may be the result of altered hepatic function. Although the PANDER−/− displays impaired GSIS, additional data is needed to substantiate that the deficiency in Ca2+ regulation of the pancreatic β-cell is causative of the insulin secretory defect and is beyond the scope of this investigation. Further studies are needed to fully establish the role of PANDER in GSIS and the molecular mechanism responsible for impaired insulin secretion. The lack of our PANDER−/− model to develop overt diabetes or chronic hyperglycemia may be potentially attributed to PANDER serving multiple functions. The hyperinsulinemic-euglycemic clamp studies showed significantly decreased hepatic glucose production and a strong trend in increased HGP suppression as compared to WT mice. This result would be directly opposing the glucose intolerance observed during the GTT, and could be limiting the higher glycemic values observed during this assay. Previous literature showing that PANDER binds to liver membranes and putatively suppresses insulin action in conjunction with the PANDER transgenic model demonstrating increased HGP is very consistent with our findings in the PANDER−/−. Our surprising result in the PANDER−/− mouse certainly suggests that PANDER may be serving multiple roles in regulating glucose levels via not only the liver but also a direct involvement within the pancreatic islet in either regulation or facilitation of insulin secretion.

Author contributions: C.E.R.C. researched data, reviewed/edited manuscript. J.R.C. researched data, reviewed/edited manuscript. C.G.W. researched data, reviewed/edited manuscript. J.Y. reviewed/edited manuscript. J.R.C. researched data. J.W. researched data. R.A.Y. researched data, reviewed/edited manuscript. B.A.W. reviewed/edited manuscript. B.R.B. designed experiments, researched data, wrote manuscript.

ACKNOWLEDGEMENTS
The authors would like to thank Klaus Kaestner, University of Pennsylvania, for valuable discussions regarding the experimental design. The authors also acknowledge Tobias Raabe from the Penn Gene Targeting Core for preparation of
murine embryonic stem cells, Jean Richa from the Penn Transgenic and Chimeric Mouse Facility for blastocyst injections, Heather Collins for performing radioimmune assays, Ravindra Dhir and director Rex Ahima of the Penn Mouse Phenotyping, Physiology, and Metabolism Core, Changhong Li and Nicolai Doliba for help with calcium-imaging experiments, and Daniel Martinez and Edward Williamson from the CHOP Pathology Core for pancreatic sectioning and subsequent confocal microscopy.

This publication was made possible through core services provided by the DERC at the University of Pennsylvania (DK19525). This work was supported by grant K01-DK070744 (to B.R.B.) from the NIDDK, National Institutes of Health, and the Juvenile Diabetes Research Foundation (to B.A.W.).

No potential conflicts of interest relevant to this article were reported.

Parts of this study were presented in abstract form and as an oral presentation at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, Louisiana, 5-9 June 2009.

REFERENCES

1. Zhu, Y, Xu, G, Patel, A, McLaughlin, MM, Silverman, C, Knecht, K, Sweitzer, S, Li, X, McDonnell, P, Mirabile, R, Zimmerman, D, Boyce, R, Tien, LA, Hu, E, Livi, GP, Wolf, B, Abd-Meguid, SS, Rose, GD, Aurora, R, Hensley, P, Briggs, M, Young, PR: Cloning, expression, and initial characterization of a novel cytokine-like gene family. *Genomics* 80:144-150, 2002

2. Cao, X, Gao, Z, Robert, CE, Greene, S, Xu, G, Xu, W, Bell, E, Campell, D, Zhu, Y, Young, R, Trucco, M, Markmann, JF, Naji, A, Wolf, BA: Pancreatic-derived factor (FAM3B), a novel islet cytokine, induces apoptosis of insulin-secreting beta-cells. *Diabetes* 52:2296-2303, 2003

3. Cao, X, Yang, J, Burkhardt, BR, Gao, Z, Wong, RK, Greene, SR, Wu, J, Wolf, BA: Effects of overexpression of pancreatic derived factor (FAM3B) in isolated mouse islets and insulin-secreting betaTC3 cells. *Am J Physiol Endocrinol Metab* 289:E543-E550, 2005

4. Yang, J, Gao, Z, Robert, CE, Burkhardt, BR, Gaweska, H, Wagner, A, Wu, J, Greene, SR, Young, RA, Wolf, BA: Structure-function studies of PANDER, an islet specific cytokine inducing cell death of insulin-secreting beta cells. *Biochemistry* 44:11342-11352, 2005

5. Burkhardt, BR, Greene, SR, White, P, Wong, RK, Brustelii, JE, Yang, J, Robert, CE, Brusko, TM, Wasserfall, CH, Wu, J, Atkins, MA, Gao, Z, Kaestner, KH, Wolf, BA: PANDER-induced cell-death genetic networks in islets reveal central role for caspase-3 and cyclin-dependent kinase inhibitor 1A (p21). *Gene* 369:134-141, 2006

6. Robert C.E., Wu J, Burkhardt BR, Wolf B: Transgenic Mice Overexpressing the Novel Islet Specific Cytokine, PANDER, Exhibit Glucose Intolerance (Abstract). *Diabetes* 54 (suppl 1): LB74, 2005

7. Yang, J, Wang, C, Li, J, Burkhardt, BR, Robert-Cooperman, CE, Wilson, C, Gao, Z, Wolf, BA: PANDER binds to the liver cell membrane and inhibits insulin signaling in HepG2 cells. *FEBS Lett* 583:3009-3015, 2009

8. Yang, J, Robert, CE, Burkhardt, BR, Young, RA, Wu, J, Gao, Z, Wolf, BA: Mechanisms of glucose-induced secretion of pancreatic-derived factor (PANDER or FAM3B) in pancreatic beta-cells. *Diabetes* 54:3217-3228, 2005

9. Wang, O, Cai, K, Pang, S, Wang, T, Qi, D, Zhu, Q, Ni, Z, Le, Y: Mechanisms of glucose-induced expression of pancreatic-derived factor in pancreatic {beta}-cells. *Endocrinology* 2007
10. Burkhardt,BR, Yang,MC, Robert,CE, Greene,SR, McFadden,KK, Yang,J, Wu,J, Gao,Z, Wolf,BA: Tissue-specific and glucose-responsive expression of the pancreatic derived factor (PANDER) promoter. *Biochim Biophys Acta* 1730:215-225, 2005

11. Burkhardt,BR, Cook, JR, Young,RA, Wolf,BA: PDX-1 interaction and regulation of the Pancreatic Derived Factor (PANDER, FAM3B) promoter. *Biochim Biophys Acta* 1779:645-651, 2008

12. Varela,GM, Antwi,DA, Dhir,R, Yin,X, Singhal,NS, Graham,MJ, Crooke,RM, Ahima,RS: Inhibition of ADRP prevents diet-induced insulin resistance. *Am J Physiol Gastrointest Liver Physiol* 295:G621-G628, 2008

13. Yang,J, Wong,RK, Park,M, Wu,J, Cook, JR, York,DA, Deng,S, Markmann,J, Naji,A, Wolf,BA, Gao,Z: Leucine regulation of glucokinase and ATP synthase sensitizes glucose-induced insulin secretion in pancreatic beta-cells. *Diabetes* 55:193-201, 2006

14. Li,C, Najafi,H, Daikhin,Y, Nissim,IB, Collins,HW, Yudkoff,M, Matschinsky,FM, Stanley,CA: Regulation of leucine-stimulated insulin secretion and glutamine metabolism in isolated rat islets. *J Biol Chem* 278:2853-2858, 2003

15. Liu,YJ, Tengholm,A, Grapengiesser,E, Hellman,B, Gylfe,E: Origin of slow and fast oscillations of Ca2+ in mouse pancreatic islets. *J Physiol* 508 (Pt 2):471-481, 1998

16. Gilon,P, Jonas,JC, Henquin,JC: Culture duration and conditions affect the oscillations of cytoplasmic calcium concentration induced by glucose in mouse pancreatic islets. *Diabetologia* 37:1007-1014, 1994

17. Eaton,RP, Allen,RC, Schade,DS: Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. *J Clin Endocrinol Metab* 56:1294-1300, 1983

18. Polonsky,KS, Rubenstein,AH: C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. *Diabetes* 33:486-494, 1984

19. Kindmark,H, Pigon,J, Efendic,S: Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction. *J Clin Endocrinol Metab* 86:2015-2019, 2001

20. Rudovich,NN, Rochlitz,HJ, Pfeiffer,AF: Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. *Diabetes* 53:2359-2365, 2004

21. Yaekura,K, Julyan,R, Wicksteed,BL, Hays,LB, Alarcon,C, Sommers,S, Poitout,V, Baskin, DG, Wang,Y, Philipson,LH, Rhodes,CJ: Insulin secretory deficiency and glucose intolerance in Rab3A null mice. *J Biol Chem* 278:9715-9721, 2003

22. Kido,Y, Burks,DJ, Withers,D, Bruning,JC, Kahn,CR, White, MF, Accili,D: Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. *J Clin Invest* 105:199-205, 2000

23. Bruning,JC, Winnay,J, Bonner-Weir,S, Taylor,SI, Accili,D, Kahn,CR: Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. *Cell* 88:561-572, 1997

24. Marie,JC, Bailbe,D, Gylfe,E, Portha,B: Defective glucose-dependent cytosolic Ca2+ handling in islets of GK and nSTZ rat models of type 2 diabetes. *J Endocrinol* 169:169-176, 2001

25. Giroix,MH, Sener,A, Bailbe,D, Leclercq-Meyer,V, Portha,B, Malaisse,WJ: Metabolic, ionic, and secretory response to D-glucose in islets from rats with acquired or inherited non-insulin-dependent diabetes. *Biochem Med Metab Biol* 50:301-321, 1993
26. Roe, MW, Philipson, LH, Frangakis, CJ, Kuznetsov, A, Mertz, RJ, Lancaster, ME, Spencer, B, Worley, JF, III, Dukes, ID: Defective glucose-dependent endoplasmic reticulum Ca2+ sequestration in diabetic mouse islets of Langerhans. *J Biol Chem* 269:18279-18282, 1994

27. Gupta, RK, Vatamaniuk, MZ, Lee, CS, Flaschen, RC, Fulmer, JT, Matschinsky, FM, Duncan, SA, Kaestner, KH: The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion. *J Clin Invest* 115:1006-1015, 2005

28. Sorensen, H, Winzell, MS, Brand, CL, Fosgerau, K, Gelling, RW, Nishimura, E, Ahren, B: Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. *Diabetes* 55:3463-3469, 2006

**FIGURE LEGENDS**

**FIG. 1. Generation and confirmation of the PANDER knockout mouse.**  
*A*: Schematic representation of genomic arrangement for mouse PANDER (top), targeting vector (middle), and the disrupted locus (bottom) produced by homologous recombination. The targeting vector was created by cloning a 4.3 kb long-arm and 2.9 kb short-arm of flanking PANDER genomic sequence surrounding the neomycin (NEO) gene in opposite orientation intended to disrupt the transcriptional start site (TSS), secretion signal peptide (SP), and exons 1 and 2. Primers 5’-F/5’-R and 3’-F/3’-R were used for confirmation of correct gene targeting resulting in a 4.3 kb and 3.5 kb product, respectively. Primers 5’-F/3’-R were utilized for routine PCR genotyping producing a 12.1 kb product for wild-type (WT), 12.1 kb/8.3 kb products for heterozygote (HET), and single 8.3 kb for knockout (KO).  
*B*: PCR analysis of genomic DNA extracted from transfected ES cells. Primer locations are shown in Figure 1A. Lane 1: molecular marker, Lanes 2 and 3: 4.3 kb arm amplified from two independent correctly targeted ES cell clones, Lanes 4 and 5: 3.5 kb arm from correctly targeted ES cell clones, Lanes 6 and 7: lack of 5’ and 3’ arm amplification from negative ES clones, and Lane 8: 4.3 kb product from artificial template consisting of a plasmid containing the 5’ arm sequence with flanking non-targeted genomic regions.  
*C*: PCR confirmation of germline transmission. Genomic DNA was extracted from tail biopsies of mouse offspring with subsequent PCR using the 5’-F/5’-R primers. Lane 1: molecular marker, Lanes 2, 3, 5, 8: mouse offspring negative for germline transmission, and Lanes 4, 6, 7: mouse offspring with targeted PANDER deletion.  
*D*: Genotyping of mouse offspring. Representative PCR results are shown among WT, HET, and KO mice.  
*E*: RT-PCR analysis of RNA isolated from PANDER positive tissues from WT, HET, and KO mice.  
*F*: Western evaluation of protein isolated from pancreatic islets for PANDER (top) and β-actin (bottom) expression from WT, HET, and KO mice.

**FIG. 2. Metabolic evaluation of PANDER−/− mice.**  
*A*: Intraperitoneal glucose tolerance test as performed by injecting mice with glucose at 2 g/kg and measuring serum glucose concentration at the indicated time points (n = 14).  
*B*: Area under the curve calculated from glycemic levels measured during the course of the glucose tolerance test.  
*C*: Intraperitoneal insulin tolerance test performed by injecting mice with insulin at 0.75 U/kg and measuring glucose concentration at indicated time points (n = 8).  
*D*: Mean steady-state glucose infusion rate (GIR) during hyperinsulinemic-euglycemic clamp (n = 8).  
*E*: Measured insulin levels during glucose tolerance test (n = 14).  
*F*: Intraperitoneal arginine tolerance test. Arginine was injected at 2 g/kg
(n = 8-9). For all experiments above, male mice approximately 4-6 months old were evaluated. Values are means ± SE. * P < 0.05, ** P < 0.01 by Student’s t test. N.S. not significant.

FIG. 3. Hepatic glucose production during hyperinsulinemic-euglycemic clamp is impaired in PANDER<sup>−/−</sup>. Hepatic glucose production during the hyperinsulinemic-euglycemic clamps was determined by subtracting the glucose infusion rate from the whole-body glucose appearance. Male mice approximately 5-7 months old were evaluated (n = 8). A: Basal hepatic glucose production and at the end of the hyperinsulinemic euglycemic clamps. B: Hepatic glucose production suppression. Values are means ± SE. * P < 0.05 by Student’s t test.

FIG. 4. Normal islet architecture and gene expression in PANDER<sup>−/−</sup> mice. Pancreatic sections from 4-6 month old male mice were evaluated via immunofluorescence for detection of insulin (green), and glucagon (red). DAPI nuclear staining is shown in blue. A: Representative micrographs of insulin and glucagon labeled pancreatic sections from PANDER wild-type (left panel) and PANDER<sup>−/−</sup> mice (right panel), respectively. B: Gene expression analysis via RT-PCR in isolated islets of PANDER<sup>−/−</sup> and wild-type mice. Various genes involved in glucose-stimulated insulin secretion were evaluated in 5-7 month old male mice (n = 3). Values are means ± SE. P = not significant for all genes as determined by Student’s t test.

FIG. 5. Islet perifusions demonstrate impaired insulin secretion in PANDER<sup>−/−</sup> mice. A: Pancreatic islets were isolated and evaluated from male mice approximately 5-7 months old. Islets were isolated and incubated with increasing concentrations of glucose of 0 mM (G0), 2 mM (G2), 5 mM (G5), 10 mM (G10), and 30 mM (G30) with a terminal step of 30 mM KCl (KCl30) at indicated times. Time at which glucose condition was increased is shown above and noted on the x-axis. Effluent fractions were collected and insulin measured by radioimmunoassay (n = 6-7). B: Area under the curve calculated for insulin secretion from the G0 to G30 condition. C: Area under curve determined for the insulin secretion during the KCl condition. D: Following conclusion of perifusion experiment, islets were collected and lysed with acid alcohol with subsequent measurement of insulin concentration via radio-immunoassay. Values are means ± SE. * P < 0.05 by Student’s t test.

FIG. 6. Abnormal calcium response to glucose stimulation in PANDER<sup>−/−</sup> islets. Intracellular calcium concentration was determined via Fura-2 during a glucose perifusion on isolated PANDER<sup>−/−</sup> and wild-type islets with stimulation from a glucose ramp and KCl (n = 3). Time of glucose increase is shown above and on x-axis. Representative calcium plots are shown. Values are means ± SE.

FIG. 7. Decreased insulin clearance in PANDER<sup>−/−</sup> mice. Intraperitoneal glucose tolerance test as performed by injecting mice with glucose at 2 g/kg and measuring serum insulin and C-peptide concentrations at the indicated time points. Male mice approximately 5-7 months old were evaluated (n = 3-6). A: Insulin; and B: C-peptide serum concentrations were determined with commercially available ELISA (ALPCO). C: C-peptide-to-insulin ratio based on area under the curve calculated from glycemic levels of insulin and C-peptide measured during the course of the glucose tolerance test. Values are means ± SE. * P < 0.05 by Student’s t test.
Figure 2

A

B

C

D

E

F

Blood Glucose (mg/dl)

Area under curve (Arbitrary units)

Blood Glucose (% of Baseline)

GIR (mg/kg/min)

Insulin (ng/ml)

Insulin (ng/ml)

Time after i.p. glucose injection (min)

Time after i.p. insulin injection (min)

Time after i.p. glucose injection (min)

Time after i.p. arginine injection (min)
Figure 3

A

HGP (mg/kg/min)

WT
KO

Basal
Clamp

B

% HGP Suppression

WT
KO
Figure 5

A

Figure 6

B

C

D

Figure 6
Figure 7

A

B

C

C-peptide/insulin ratio

WT
KO

Time after IP glucose injection (min)

Insulin (ng/ml)

Time after IP glucose injection (min)

C-peptide (ng/ml)